FDA Approves First Nasal Spray For Dry Eye Disease From Oyster Point Pharma

• The FDA has approved Oyster Point Pharma Inc (NASDAQ: OYST) Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for signs and symptoms of dry eye disease.

• Tyrvaya Nasal Spray is the first and only nasal spray approved for dry eye disease.

• Related: Oyster Point Inks License Pact With Ji Xing Pharma For Dry Eye Disease Candidates In Greater China.

• Tyrvaya binds to cholinergic receptors to activate the trigeminal parasympathetic pathway resulting in increased production of the basal tear film as a treatment for dry eye disease.

• Tyrvaya will be available from next month in cartons containing two multidose nasal spray bottles.

• Each nasal spray bottle covers treatment for 15 days, administered twice daily into each nostril.

• Related content: Benzinga's Full FDA Calendar.

• Price Action: OYST shares closed 1.91% higher at $13.86 on Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US

• Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.